OBJECTIVES/HYPOTHESIS: Malignant transformation of laryngeal keratosis has been reported in a substantial subset of patients, yet reliable criteria for predicting patients most at risk have yet to be determined. Current methods for determining dysplasia ratings are susceptible to errors in biopsy sampling and interpretation. An understanding of the genetic underpinnings of the progression of vocal fold tumorigenesis may contribute to the creation of reliable and predictive diagnostic criteria. We hypothesized that genetic expression markers distinguish patients with keratotic noncancerous vocal fold lesions from invasive carcinoma. STUDY DESIGN: Observational cross-sectional study. METHODS: Real-time polymerase chain reaction (RT-PCR) was used to compare expression of 84 cancer pathway genes of patients following histologic diagnosis of nondysplastic keratotic epithelium (ND) (n = 7), dysplastic keratotic epithelium (DYS) (n = 3), and invasive carcinoma (CA) (n = 7). All patients had a clinical diagnosis of leukoplakia, and biopsies were obtained from true vocal fold tissue. RESULTS: Four genes (IGF-1, EPDR1, MMP-2, S100A4) were significantly upregulated in DYS over the ND group. Seven genes were significantly upregulated in CA over the DYS group, and 31 genes were significantly upregulated in CA over the ND group (P < .02). The expression of matrix metalloproteinases (MMP-1, MMP-2, MMP-9) was found to statistically differentiate the groups (P < .02) and suggested disease progression associated with extracellular matrix degradation and angiogenesis promotion. CONCLUSIONS: With these preliminary array data, we demonstrate the feasibility of using RT-PCR to identify distinct genetic expression between diagnostic groups. Characterization of genetic changes marking the progression of vocal fold tumorigenesis may lead to robust diagnostic criteria in the future.
OBJECTIVES/HYPOTHESIS: Malignant transformation of laryngeal keratosis has been reported in a substantial subset of patients, yet reliable criteria for predicting patients most at risk have yet to be determined. Current methods for determining dysplasia ratings are susceptible to errors in biopsy sampling and interpretation. An understanding of the genetic underpinnings of the progression of vocal fold tumorigenesis may contribute to the creation of reliable and predictive diagnostic criteria. We hypothesized that genetic expression markers distinguish patients with keratotic noncancerous vocal fold lesions from invasive carcinoma. STUDY DESIGN: Observational cross-sectional study. METHODS: Real-time polymerase chain reaction (RT-PCR) was used to compare expression of 84 cancer pathway genes of patients following histologic diagnosis of nondysplastic keratotic epithelium (ND) (n = 7), dysplastic keratotic epithelium (DYS) (n = 3), and invasive carcinoma (CA) (n = 7). All patients had a clinical diagnosis of leukoplakia, and biopsies were obtained from true vocal fold tissue. RESULTS: Four genes (IGF-1, EPDR1, MMP-2, S100A4) were significantly upregulated in DYS over the ND group. Seven genes were significantly upregulated in CA over the DYS group, and 31 genes were significantly upregulated in CA over the ND group (P < .02). The expression of matrix metalloproteinases (MMP-1, MMP-2, MMP-9) was found to statistically differentiate the groups (P < .02) and suggested disease progression associated with extracellular matrix degradation and angiogenesis promotion. CONCLUSIONS: With these preliminary array data, we demonstrate the feasibility of using RT-PCR to identify distinct genetic expression between diagnostic groups. Characterization of genetic changes marking the progression of vocal fold tumorigenesis may lead to robust diagnostic criteria in the future.
Authors: Thomas J Belbin; Bhuvanesh Singh; Ilana Barber; Nicholas Socci; Bruce Wenig; Richard Smith; Michael B Prystowsky; Geoffrey Childs Journal: Cancer Res Date: 2002-02-15 Impact factor: 12.701
Authors: Shi-Long Lu; Douglas Reh; Allen G Li; Jennifer Woods; Christopher L Corless; Molly Kulesz-Martin; Xiao-Jing Wang Journal: Cancer Res Date: 2004-07-01 Impact factor: 12.701
Authors: Rebecca S Bartlett; Joel D Gaston; Shuyun Ye; Christina Kendziorski; Susan L Thibeault Journal: J Biomech Date: 2018-12-07 Impact factor: 2.712
Authors: L Staníková; J Šatanková; H Kučová; R Walderová; K Zeleník; Pavel Komínek Journal: Eur Arch Otorhinolaryngol Date: 2016-08-11 Impact factor: 2.503
Authors: F Gimeno-Valiente; Á L Riffo-Campos; G Ayala; N Tarazona; V Gambardella; F M Rodríguez; M Huerta; C Martínez-Ciarpaglini; J Montón-Bueno; S Roselló; D Roda; A Cervantes; L Franco; G López-Rodas; J Castillo Journal: Sci Rep Date: 2020-02-28 Impact factor: 4.379